Kiniksa Pharmaceuticals Reports Q1 GAAP EPS of $0.27 and Revenue of $214.3M
Kiniksa Pharmaceuticals (KNSA) reported Q1 GAAP earnings per share of $0.27, surpassing expectations by $0.09, and revenue of $214.3 million, which exceeded forecasts by $8.21 million. The company also raised its 2026 ARCALYST net product revenue guidance to between $930 million and $945 million.
Tickers: $KNSA
Topics: earnings financial performance guidance revenue